RHA 2, RHA 3, RHA 4

FDA Premarket Approval P170002 S013

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

To declare the change of analytical laboratory in charge of the assay of sodium hyaluronate (naha) content in the finished products at the release step for rha2, rha3, and rha4

DeviceRHA 2, RHA 3, RHA 4
Generic NameImplant, Dermal, For Aesthetic Use
ApplicantTEOXANE S.A.
Date Received2021-02-17
Decision Date2021-03-19
PMAP170002
SupplementS013
Product CodeLMH 
Advisory CommitteeGeneral & Plastic Surgery
Supplement Type30-day Notice
Supplement ReasonProcess Change - Manufacturer/sterilizer/packager/supplier
Expedited ReviewNo
Combination Product Yes
Applicant Address TEOXANE S.A. rue De Lyon 105 geneva 1203

Supplemental Filings

Supplement NumberDateSupplement Type
P170002Original Filing
S013 2021-02-17 30-day Notice
S012
S011
S010 2020-07-20 135 Review Track For 30-day Notice
S009 2020-02-14 30-day Notice
S008 2020-02-13 30-day Notice
S007 2019-11-13 30-day Notice
S006
S005 2019-06-18 Real-time Process
S004 2019-03-12 135 Review Track For 30-day Notice
S003 2019-03-12 30-day Notice
S002 2019-02-21 30-day Notice
S001

© 2021 FDA.report
This site is not affiliated with or endorsed by the FDA.